Scientific Nexus
Vol. 2 No. 2 (2026): Scientific Nexus

Sanggenon C from Morus alba as a promising Bcl-2 inhibitor: a molecular docking study targeting apoptosis in lung cancer

Adelweis Putrinda (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Anisa Salwa Razika (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Dewi Nadia Luthfi (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Nabila Tri Elmerillia (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Nabilla Intan Safira (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Anjar Hermadi Saputro (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)
Winni Nur Auli (Department of Pharmacy, Faculty of Science, Institut Teknologi Sumatera, South Lampung 35365, Lampung, Indonesia)



Article Info

Publish Date
22 Aug 2026

Abstract

Bcl-2 overexpression is a key driver of apoptosis evasion and chemoresistance in lung cancer. Morus alba L. harbors bioactive phytochemicals with reported anticancer properties, yet their binding potential against Bcl-2 remains computationally unevaluated. This study aims to assess the binding affinity and interaction profiles of five M. alba-derived compounds—sanggenon C, morusin, albanol B, rutin, and kuwanon C—against Bcl-2 using molecular docking. Molecular docking was performed using AutoDockTools® (v1.5.7) with the Bcl-2 crystal structure (PDB ID: 6O0K) and venetoclax as the reference ligand. Binding free energy (ΔG), binding site similarity (%BSS), and hydrogen bond interactions were analyzed. Redocking yielded an RMSD of 1.41 Å, confirming protocol validity. Sanggenon C exhibited the most favorable binding profile (ΔG = −8.46 kcal/mol; %BSS = 81.25%), sharing 13 of 16 key residues with venetoclax, including Phe112, Val156, Met115, Phe153, Arg146, and Gly145, with three hydrogen bonds predominantly within the optimal range. These findings establish a computational basis for prioritizing sanggenon C as a Bcl-2 inhibitor lead from M. alba, warranting further validation through ADMET profiling, molecular dynamics simulation, and in vitro cytotoxicity and apoptosis assays in lung cancer cell models.

Copyrights © 2026






Journal Info

Abbrev

scinexus

Publisher

Subject

Astronomy Chemistry Earth & Planetary Sciences Materials Science & Nanotechnology Medicine & Pharmacology

Description

Scientific Nexus is a peer-reviewed scientific journal publishing research articles, review articles, short communications, editorials, and perspectives within the scope of Science, covering but not limited to: Physics Biomedicine Chemistry Drug Discovery and Development Atmospheric and Planetary ...